Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

References

• IARC, Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages; 2021. Available from: https://gco.iarc.fr/today/en. Accessed March, 2022.
   Google Scholar
• Compérat E, Larré S, Roupret M, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015;466:589–594. doi:10.1007/s00428-015-1739-2
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79:480–488. doi:10.1016/j.eururo.2020.12.033
   PubMed Web of Science ®Google Scholar
• Psutka SP, Barocas DA, Catto JWF, et al. Staging the host: personalizing risk assessment for radical cystectomy patients. Eur Urol Oncol. 2018;1:292–304. doi:10.1016/j.euo.2018.05.010
   PubMed Web of Science ®Google Scholar
• Tse J, Singla N, Ghandour R, Lotan Y, Margulis V. Current advances in BCG-unresponsive non-muscle invasive bladder cancer. Expert Opin Investig Drugs. 2019;28:757–770. doi:10.1080/13543784.2019.1655730
   PubMed Web of Science ®Google Scholar
• Meghani K, Cooley LF, Choy B, et al. First in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to Bacillus Calmette-Guérin. Eur Urol. 2022;82:602–610. doi:10.1016/j.eururo.2022.08.004
   PubMed Web of Science ®Google Scholar
• Moe A, Liow E, Redfern A, et al. A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol. BJU Int. 2021;128(Suppl 1):9–17. doi:10.1111/bju.15365
   PubMedGoogle Scholar
• Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, Phase 2 study. Lancet Oncol. 2021;22:919–930. doi:10.1016/S1470-2045(21)00147-9
   PubMed Web of Science ®Google Scholar
• Black PC, Tangen C, Singh P, et al. Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). J Clin Oncol. 2020;38(15 Suppl):5022. doi:10.1200/JCO.2020.38.15_suppl.5022
   Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876–883. doi:10.1200/JCO.2006.08.3311
   PubMed Web of Science ®Google Scholar
• Mangsbo SM, Broos S, Fletcher E, et al. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell–dependent tumor immunity. Clin Cancer Res. 2015;21:1115–1126. doi:10.1158/1078-0432.CCR-14-0913
   PubMed Web of Science ®Google Scholar
• Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478–480. doi:10.1038/30996
   PubMed Web of Science ®Google Scholar
• Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical Bacillus Calmette-Guérin. J Urol. 2013;190:1200–1204. doi:10.1016/j.juro.2013.04.031
   PubMed Web of Science ®Google Scholar
• Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after Bacillus Calmette-Guérin treatment failure. J Urol. 2013;190:1686–1691. doi:10.1016/j.juro.2013.04.120
   PubMed Web of Science ®Google Scholar
• Steinberg GD, Smith ND, Ryder K, Strangman NM, Slater SJ. Factors Affecting valrubicin response in patients with Bacillus Calmette-Guérin-refractory bladder carcinoma in situ. Postgrad Med. 2011;123:28–34. doi:10.3810/pgm.2011.05.2281
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of Bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186:448–451. doi:10.1016/j.juro.2011.03.129
   PubMed Web of Science ®Google Scholar
• Bassi PF, Volpe A, D’Agostino D, et al. Paclitaxel-hyaluronic acid for intravesical therapy of Bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol. 2011;185:445–449. doi:10.1016/j.juro.2010.09.073
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010;116:1893–1900. doi:10.1002/cncr.24914
   PubMed Web of Science ®Google Scholar
• Perdonà S, Di Lorenzo G, Cantiello F, et al. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2010;21:101–106. doi:10.1097/CAD.0b013e3283324d83
   PubMed Web of Science ®Google Scholar
• Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2010;75:134–137. doi:10.1016/j.urology.2009.06.112
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28:543–548. doi:10.1200/JCO.2008.20.8199
   PubMed Web of Science ®Google Scholar
• Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or Carcinoma In Situ (CIS) refractory to prior therapy with Bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009;27:496–501. doi:10.1016/j.urolonc.2008.05.004
   PubMed Web of Science ®Google Scholar
• Mohanty NK, Nayak RL, Vasudeva P, Arora RP. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol. 2008;26:616–619. doi:10.1016/j.urolonc.2007.10.016
   PubMed Web of Science ®Google Scholar
• Gunelli R, Bercovich E, Nanni O, et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a Translational Study. Br J Cancer. 2007;97:1499–1504. doi:10.1038/sj.bjc.6604074
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24:2729–2734. doi:10.1200/JCO.2005.05.2720
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II Prospective Multicenter Study. Urology. 2005;66:726–731. doi:10.1016/j.urology.2005.04.062
   PubMed Web of Science ®Google Scholar
• Bassi P, De Marco V, Tavolini IM, et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to Bacillus Calmette-Guérin therapy. Urol Int. 2005;75:309–313. doi:10.1159/000089164
   PubMed Web of Science ®Google Scholar
• Chevuru PT, McElree IM, Mott SL, Steinberg RL, O’Donnell MA, Packiam VT. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urol Oncol. 2023;41:148.e1–148.e7. doi:10.1016/j.urolonc.2022.10.030
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. 2020;203:902–908. doi:10.1097/JU.0000000000000688
   PubMed Web of Science ®Google Scholar
• DeCastro GJ, Sui W, Pak JS, et al. A Phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive Bacillus Calmette-Guérin unresponsive or recurrent/relapsing urothelial carcinoma of the bladder. J Urol. 2020;204:247–253. doi:10.1097/JU.0000000000000919
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Benfante N, Sjoberg DD, et al. Single Arm Phase I/II Study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed Bacillus Calmette Guerin (NCT01259063). Bladder Cancer. 2017;3:113–119. doi:10.3233/BLC-170095
   PubMed Web of Science ®Google Scholar
• Cockerill PA, Knoedler JJ, Frank I, Tarrell R, Karnes RJ. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. BJU Int. 2016;117:456–462. doi:10.1111/bju.13088
   PubMed Web of Science ®Google Scholar
• Lightfoot AJ, Breyer BN, Rosevear HM, Erickson BA, Konety BR, O’Donnell MA. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. Urol Oncol. 2014;32:35.e15–35.e19. doi:10.1016/j.urolonc.2013.01.009
   PubMed Web of Science ®Google Scholar
• Hurle R, Casale P, Morenghi E, et al. Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a Single-Arm, Open-Label Study. BJUI Compass. 2020;1:126–132. doi:10.1002/bco2.28
   PubMedGoogle Scholar
• Milbar N, Kates M, Chappidi MR, et al. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer. 2017;3:293–303. doi:10.3233/BLC-170126
   PubMed Web of Science ®Google Scholar
• Robins DJ, Sui W, Matulay JT, et al. Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous Bacillus Calmette-guérin therapy. Urology. 2017;103:149–153. doi:10.1016/j.urology.2017.01.018
   PubMed Web of Science ®Google Scholar
• Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous Bacillus Calmette-Guérin therapy. J Urol. 2013;189:834–839. doi:10.1016/j.juro.2012.10.068
   PubMed Web of Science ®Google Scholar
• Hendricksen K. Device-assisted intravesical therapy for non-muscle invasive bladder cancer. Transl Androl Urol. 2019;8:94–100. doi:10.21037/tau.2018.09.09
   PubMed Web of Science ®Google Scholar
• Van der Heijden AG, Verhaegh G, Jansen CF, et al. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 2005;173:1375–1380. doi:10.1097/01.ju.0000146274.85012.e1
   PubMed Web of Science ®Google Scholar
• Paroni R, Salonia A, Lev A, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol. 2001;52:273–278. doi:10.1046/j.0306-5251.2001.01449.x
   PubMed Web of Science ®Google Scholar
• Liem EIML, Crezee H, de la Rosette JJ, de Reijke TM. Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations. Int J Hyperth. 2016;32:363–373. doi:10.3109/02656736.2016.1155760
   PubMed Web of Science ®Google Scholar
• Longo TA, Gopalakrishna A, Tsivian M, et al. A systematic review of regional hyperthermia therapy in bladder cancer. Int J Hyperthermia. 2016;32:381–389. doi:10.3109/02656736.2016.1157903
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21(23):4270–4276. doi:10.1200/JCO.2003.01.089
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–918. doi:10.1111/j.1464-410X.2010.09654.x
   PubMed Web of Science ®Google Scholar
• Arends TJ, Nativ O, Maffezzini M, et al. Results of a Randomised controlled trial comparing intravesical chemohyperthermia with Mitomycin C versus Bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69:1046–1052. doi:10.1016/j.eururo.2016.01.006
   PubMed Web of Science ®Google Scholar
• Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after Bacillus Calmette-Guerin. J Urol. 2009;182(4):1313–1317. doi:10.1016/j.juro.2009.06.017
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high-risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777–782. doi:10.1097/01.ju.0000080568.91703.18
   PubMed Web of Science ®Google Scholar
• Zahoor H, Mir MC, Barata PC, et al. Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. Investig New Drugs. 2019;37:1231–1238. doi:10.1007/s10637-018-00716-w
   PubMed Web of Science ®Google Scholar
• Hahn NM, Bivalacqua TJ, Ross AE, et al. A Phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier cancer research network trial HCRN 12-157. Clin Cancer Res. 2017;23:3003–3011. doi:10.1158/1078-0432.CCR-16-2267
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22:107–117. doi:10.1016/S1470-2045(20)30540-4
   PubMed Web of Science ®Google Scholar
• Packiam VT, Lamm DL, Barocas DA, et al. An open label, single-arm, phase II Multicenter Study of the Safety and Efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol. 2018;36:440–447. doi:10.1016/j.urolonc.2017.07.005
   PubMed Web of Science ®Google Scholar
• Shore ND, Boorjian SA, Canter DJ, et al. Intravesical RAd-IFNα/Syn3 for patients with high-grade, Bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a Phase II Randomized Study. J Clin Oncol. 2017;35:3410–3416. doi:10.1200/JCO.2017.72.3064
   PubMed Web of Science ®Google Scholar
• Navai N, Benedict WF, Zhang G, et al. Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon A2b formulated in Syn3 for failures of Bacillus Calmette-Guerin (BCG) therapy in nonmuscle invasive bladder cancer. Ann Surg Oncol. 2016;23:4110–4114. doi:10.1245/s10434-016-5300-6
   PubMed Web of Science ®Google Scholar
• Dinney CPN, Fisher MB, Navai N, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-A2b formulated in syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190:850–856. doi:10.1016/j.juro.2013.03.030
   PubMed Web of Science ®Google Scholar
• Benedict WF, Tao Z, Kim CS, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004;10:525–532. doi:10.1016/j.ymthe.2004.05.027
   PubMed Web of Science ®Google Scholar
• Connor RJ, Anderson JM, Machemer T, Maneval DC, Engler H. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology. 2005;66:224–229. doi:10.1016/j.urology.2005.02.015
   PubMed Web of Science ®Google Scholar
• Yamashita M, Rosser CJ, Zhou JH, et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther. 2002;9:687–691. doi:10.1038/sj.cgt.7700488
   PubMed Web of Science ®Google Scholar
• Chu C, Pietzak E. Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: invited review for special issue ”seminar: treatment advances and molecular biology insights in urothelial carcinoma”. Urol Oncol. 2023;41:398–409. doi:10.1016/j.urolonc.2022.05.013
   PubMed Web of Science ®Google Scholar
• Chang SS, Chamie K, Gonzalgo ML, et al. Positive efficacy and safety Phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RFc superagonist N-803 (Anktiva) and BCG infusion. J clin oncol. 2022;40:431. doi:10.1200/JCO.2022.40.6_suppl.431
   Web of Science ®Google Scholar
• Morales A, Herr H, Steinberg G, et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with Bacillus Calmette-Guérin. J Urol. 2015;193:1135–1143. doi:10.1016/j.juro.2014.09.109
   PubMed Web of Science ®Google Scholar
• Kowalski M, Guindon J, Brazas L, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with Bacillus Calmette-Guérin. J Urol. 2012;188:1712–1718. doi:10.1016/j.juro.2012.07.020
   PubMed Web of Science ®Google Scholar
• Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009;181:1040–1045. doi:10.1016/j.juro.2008.11.019.
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA. Final results from a national multicenter Phase II trial of combination Bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24:344–348. doi:10.1016/j.urolonc.2005.11.026
   PubMed Web of Science ®Google Scholar
• O’Donnell MA, Lilli K, Leopold C. Interim results from a national multicenter Phase II trial of combination Bacillus Calmette-Guerin plus interferon Alfa-2b for superficial bladder cancer. J Urol. 2004;172:888–893. doi:10.1097/01.ju.0000136446.37840.0a
   PubMed Web of Science ®Google Scholar
• Chu CE, Sjöström M, Egusa EA, et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res. 2021;27:5123–5130. doi:10.1158/1078-0432.CCR-20-4175
   PubMed Web of Science ®Google Scholar
• Kamat AM, Steinberg GD, Inman BA, et al. Study EV-104: phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC)—trial in progress. J Clin Oncol. 2023;41:TPS582. doi:10.1200/JCO.2023.41.6_suppl.TPS582
   Google Scholar
• Lee JY, Diaz RR, Cho KS, et al. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guerin immunotherapy. J Urol. 2013;190:1192–1199.
   PubMed Web of Science ®Google Scholar
• Waidelich R, Stepp H, Baumgartner R, et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol. 2001;165:1904–1907. doi:10.1016/S0022-5347(05)66239-8
   PubMed Web of Science ®Google Scholar
• Ritch CR, Velasquez MC, Kwon D, et al. Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol. 2020;203(3):505–511. doi:10.1097/JU.0000000000000593
   PubMed Web of Science ®Google Scholar
• Zuiverloon TCM, Zwarthoff EC. Predicting response to intravesical Bacillus Calmette-Güerin immunotherapy: are we moving forward? Eur Urol. 2016;69:201–202. doi:10.1016/j.eururo.2015.07.010
   PubMed Web of Science ®Google Scholar
• Kamat AM, Sylvester RJ, B€ohle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol. 2016;34:1935–1944. doi:10.1200/JCO.2015.64.4070
   PubMed Web of Science ®Google Scholar
• Lerner SP, Dinney C, Kamat A, et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer. 2015;1:29–30.
   PubMed Web of Science ®Google Scholar
• Cui J, Wang W, Chen S, et al. Combination of intravesical chemotherapy and Bacillus Calmette-Guerin versus Bacillus Calmette-Guerin monotherapy in intermediate- and high-risk nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Medicine. 2016;95:e2572. doi:10.1097/MD.0000000000002572
   PubMed Web of Science ®Google Scholar
• Arends TJ, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192:708–713. doi:10.1016/j.juro.2014.03.101
   PubMed Web of Science ®Google Scholar